BRCA2 and ovarian carcinoma: Several mechanisms of PARPi resistance have been identified in vitro (e.g. cancer cell lines and patient-derived organoids) and in vivo (clinical samples) with significant differences based on genetic background (e.g. BRCA1 vs. BRCA2 mutant) and tumor types (e.g. breast vs. ovarian cancer).